Objective: Plasma Epstein-Barr virus (EBV) DNA concentration at the time of diagnosis (pre-EBV) can be used to stratify risk for nasopharyngeal cancer (NPC) patients. However, pre-EBV cut-off values vary among studies. Methods: This was a post hoc analysis of 208 NPC patients from a phase II/III study comparing sequential (SEQ) vs. simultaneous integrated boost (SIB) intensity modulated radiation therapy. The objective was to identify the optimal pre-EBV cut-off value to predict overall survival (OS), progression free survival (PFS) and distant metastatic free survival (DMFS) rates. Results: The pre-EBV and post-treatment EBV DNA (post-EBV) were detectable in 59.1% and 3.8% of the patients, respectively. A new pre-EBV cut-off value of 2300 copies/ml was identified by the receiver operating characteristics analysis. This cut-off value showed 82% sensitivity, 59% specificity and 31.7% positive and 93.5% negative predictive values in predicting OS. The 3-year OS, PFS and DMFS were 95.6 vs. 73.8%, 89.8 vs. 55.3% and 93 vs. 70.1% for pre-EBV < vs. ≥2300 copies/ml, respectively. Older age group (≥45 years), high pre-EBV and detectable post-EBV concentration were independent predictors for OS, PFS and DMFS in a multivariate analysis. When the stage grouping and pre-EBV value were combined, a subgroup of patients with stage II-III and pre-EBV values <2300 copies/ml. had the best survival outcomes, while the worst survival subgroup was the patients with stage III-IVb with pre-EBV values ≥2300 copies/ml. Conclusions: Pre-EBV cut-off of 2300 copies/ml is an optimal value predicting OS, PFS and DMFS.
Introduction
Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) in an endemic area. In recent decades, the use of precise imaging and intensity modulated radiation therapy (IMRT) in the radiation oncology community has shifted the pattern of recurrence from locoregional recurrence toward distant metastasis. Although concurrent chemotherapy with radiation therapy (RT) in a locally advanced stage has been accepted as a standard treatment because of the overall survival (OS) and progression free survival (PFS) advantages compared to RT alone (1) (2) (3) , the distant metastatic free survival (DMFS) rate still varied between 80 and 83% (4) (5) (6) (7) .
The circulating plasma EBV DNA concentration at the time of diagnosis can be used as a prognostic marker to identify high-risk patients who may benefit from more intensified treatments (8) . To predict the overall survival, pretreatment EBV DNA (pre-EBV) cut-off values vary among studies. The most commonly used values were 4000 copies per ml (9) (10) (11) and 1500 copies per ml (12) (13) (14) (15) . Others detected cut-off values of 2010 copies per ml (16) and 50 000 copies per ml (17) . However, studies comparing these established pre-EBV cut-off values are scarce. In light of these controversies, our primary endpoint was to identify the optimal pre-EBV cut-off value to predict OS, PFS and DMFS rates. Additionally, a comparison of the survival outcomes using our new cut-off value and the previous ones was also conducted.
Material and methods
This study was a secondary analysis of a prospective randomized controlled trial comparing the utility of sequential (SEQ) or simultaneous integrated boost (SIB) IMRT in non-metastatic nasopharyngeal cancer (18, 19) . This study was approved by the institutional review board (IRB no. 424/53). Informed consent was obtained from every patient before study entry. Briefly, all patients with newly diagnosed stage I-IVB NPC patients were enrolled. Staging classification was made according to the 2010 seventh edition American Joint Committee on Cancer (AJCC). The majorities of the patients had undifferentiated squamous cell carcinoma and were male. Quantitative measurement of plasma EBV DNA level Plasma EBV DNA concentrations were evaluated before (pre-EBV), at the fifth week of the radiation course and 3 months after the completion of radiation treatment (post-EBV). The EBV nucleic acids were purified from the plasma samples using the QIAsymphony SP in combination with QIAsymphony DSP Virus/Pathogen Midi Kit (QIAGEN, Germany) using the manufacturer's recommended protocol. After extraction, the eluates in the 96-microwell plates were transferred to the module for assembling with master mix (QIAGEN artus EBV QS RGQ kit) by the instrument. The aliquoted reactions were subsequently put in a Rotor-Gene Q. The amplification parameters were as follows: 95°C for 10 min and then 45 cycles of 95°C for 15 s, 65°C for 30 s, and 72°C for 20 s. The plasma DNA samples were quantified for EBV DNA using a RTQ-PCR system targeting the BamHI-W fragment region of the EBV genome. A plasma EBV DNA concentration of <316 copies/ml was defined as an undetectable level in our institution. Note that for the following section, values of 0 represent an undetectable plasma EBV DNA concentration.
Statistical analysis
OS, PFS and DMFS rates were analyzed using the Kaplan-Meier method and the log-rank test. OS was defined as the date of treatment initiation to the date of death. PFS was defined as the date of treatment initiation to the date of either disease progression or death. For DMFS, the duration was measured from the date of the start of radiation treatment to the date of the distant metastasis event or censored at the last follow-up date. A Cox proportional hazard model with univariable and multivariable analyses was performed to identify predictors for survival outcomes. Factors including age, sex, stage, pre-EBV, post-EBV, WHO subtypes and IMRT techniques were included as covariates in this exploratory analysis. The multivariable model only included one pre-EBV value at one time during the statistical analysis to avoid multicollinearity. Factors with a P-value of <0.25 in the univariate analysis were entered into the multivariate Cox regression model. The optimal cut-off was determined using a receiver operating characteristics (ROC) analysis. Youden's index was performed in order to identify a new cut-off value that maximized the difference between the sensitivity and specificity and between the real-positive and false-positive subjects. Finally, the value was tested using a multivariate Cox regression analysis. All the tests were two-sided, and a P-value of <0.05 was considered statistically significant. The statistical analyses were performed using IBM SPSS statistics (version 22.0, SPSS Inc., Chicago, IL, USA).
Results
Between October 2010 and September 2015, 221 eligible biopsyproven stage I-IVB NPC patients were randomly allocated to the treatment arms. After excluding 5 patients who withdrew during RT, 7 patients who were lost to follow-up after chemotherapy and one stage I patient, there were 208 patients in the analysis of the outcomes (Fig. 1) . The median age was 49 years old. The patient characteristics are outlined in Table 1 . Approximately, 54% of the patients were stage III. The median follow-up time was 41 months (range 5.5-84 months). All the patients received a median of six cycles of concurrent weekly cisplatin (86% received ≥5 cycles) and a median of three cycles of adjuvant chemotherapy (75% completed three cycles). The pre-EBV was detectable in 59.1% of the patients. The post-EBV was detectable in 8/208 (3.8%) patients.
Plasma EBV DNA level correlated with disease and treatment outcomes
The median pre-EBV value for the entire patient set was 2000 copies/ ml. The corresponding values for stage II, III and IV were 0 copies/ml. (Interquartile range (IQR), 0-3470), 2000 copies/ml (IQR, 0-9705) and 5620 copies/ml (IQR, 0-12 950), respectively.
A new pre-EBV cut-off of 2300 copies/ml was identified by the ROC analysis as a good predictor for OS, PFS and DMFS, with an area under the curve of 0.709, 0.742 and 0.703 (Fig. 2) . The new cut-off showed 82% sensitivity and 59% specificity when differentiating OS among the patients. The positive (PPV) and negative predictive values (NPV) of this cut-off value for OS were 31.7 and 93.5%, respectively. Our pre-EBV cut-off value demonstrated a balance between high sensitivity, high specificity and high NPV.
Survival outcomes
During the follow-up period, a total of 39 patients died and 40 developed distant metastases. The 3-year OS rates for stage II, III and IV were 92.9, 89.1 and 73.8%, respectively (P = 0.006), while the 3-year PFS was 89.2, 78.7 and 55.1%, respectively (P < 0.001) (Fig. 3) . The corresponding 3-year DMFS was 95.8, 84.2 and 72.1%, respectively (P = 0.020). The unadjusted univariate analyses for the clinical parameters and the EBV value associated with OS, DMFS and PFS are shown in Table 2 . Younger age group (<45 years), early T-stage (T1-2), N0-2 stage, stage II-III group, low pre-EBV and undetectable post-EBV values were significantly associated with a better OS.
In the multivariate analysis, younger age group (<45 years), low pre-EBV and undetectable post-EBV values were significant predictors for OS, PFS and DMFS (Table 3 ). Stages II-III was a prognostic factor for OS, not PFS and DMFS. The most important prognostic factors, in terms of the OS, were an undetectable post-EBV (P < 0.001, hazard ratio (HR) = 0.163, 95% CI 0.063-0.421), followed by a pre-EBV cut-off value <2300 copies/ml. (P < 0.001, HR = 0.216, 95% CI 0.093-0.501).
The survival difference between the various pre-EBV cut-off values is shown in Table 4 . Using the cut-off value of 2300, the 3-year OS, PFS and DMFS were 95.6 vs. 73.8%, 89.8 vs. 55.3% and 93 vs. 70.1% for the lower than pre-EBV cut-off group vs. the equal or higher than pre-EBV cut-off group, respectively (P < 0.001). Due to the small number of patients with detectable post-EBV, we did not perform the ROC analysis to define the post-EBV cut-off. The 3-year OS, PFS and DMFS were 86.7 vs. 37.5%, 75.7 vs. 0% and 84.7 vs. 14.6% for the undetectable post-EBV vs. the detectable post-EBV, respectively (P < 0.001).
A combination of the stage grouping and the pre-EBV values stratified the patients into three subgroups as follows: (1) the low-risk grouppatients with stage II-III with pre-EBV values <2300 copies/ml; (2) the intermediate-risk group-patients with stage II and pre-EBV values ≥2300 copies/ml or patients with stage IV with pre-EBV values <2300 copies/ml and (3) the high-risk group-patients with stage III-IV with Figure 4 demonstrates the OS, PFS and DMFS among these subgroups. An exploratory combination of the age group and the pre-EBV values also identified the best subgroup which was patients with age <45 year with pre-EBV values <2300 copies/ml. The worst subgroup was patients with age ≥45 years with pre-EBV values ≥2300 copies/ml (Fig. 5) .
Discussion
There are increasing numbers of studies demonstrating the consistency of the pre-EBV value in prognostication of the OS in NPC. Various pre-EBV cut-off values have been evaluated among many studies, and the higher cut-off value levels were always associated with a higher mortality and poorer PFS as well as poorer DMFS (8) . The most commonly used pre-EBV cut-off values were 4000 copies/ml (9-11) and 1500 copies/ml (12) (13) (14) (15) . However, these studies used the AJCC fifth-sixth edition, did not routinely use MRI for staging, did not uniformly give concurrent chemotherapy, and were performed before the IMRT era. Chan et al. (9) treated 170 NPC patients with conventional RT, and 15 of these received weekly concurrent cisplatin. By using a regression tree analysis, log-rank test and Cox regression model, a pre-EBV cut-off value of 4000 copies/ml. was identified and was a highly statistically significant prognostic factor in the multivariate analysis for PFS (P = 0.023) and OS (P < 0.001) but not for LPFS (P = 0.064) and DMFS (P = 0.182). Leung et al. (10) retrospectively reviewed 376 NPC patients with all stages who were treated with conventional RT between the year 1993-2000. Only 38 patients received concurrent cisplatin with radiation therapy. In their multivariate analysis, only pre-EBV was an independent prognostic factor for OS (P = 0.0053) and DMFS (P = 0.0002) followed by AJCC stage (1997). Lin et al. (12) established the pre-EBV cut-off value of 1500 copies per ml. by evaluating 99 AJCC 1997 stage III-IV NPC patients who were treated with neoadjuvant cisplatin and 5FU followed by conventional radiation therapy. A pre-EBV cut-off value of 1500 copies per ml. was a significant prognostic factor for OS (P < 0.001) and relapse-free survival (P = 0.02). Comparison among various studies using different EBV cut-off is detailed in Table 5 .
Our study was the secondary analysis from a prospective randomized study that identified a pre-EBV cut-off value to predict treatment outcomes in the era of IMRT, and standard concurrent chemoradiation was given to the patients with locally advanced disease. Lee et al. (20) found that detectable pre-EBV was a worse prognostic for LPFS, RPFS, DMFS and PFS in their retrospective study of 260 NPC patients treated with IMRT with or without chemotherapy. Peng et al. (16) reported that pre-EBV was an independent prognostic factor for DFS, OS, DMFS and LRRFS. Our study demonstrated that the pre-EBV was prognostic for OS, PFS and DMFS.
To establish the best cut-off value in terms of the sensitivity and specificity for OS, a ROC curve was initiated and showed that the new cutoff value of 2300 copies/ml. had a higher NPV (93.5%) as well as a higher sensitivity (82%) compared to other previously reported cut-off values. In Chan et al.'s study (9) , the PPV and NPV for the pre-EBV cutoff of 4000 copies/ml were 41 and 93%. However, when applying this cut-off value in our patient population, the PPV and NPV were reduced to 32.9 and 90.6%, respectively. Recently, Peng et al. (16) retrospectively reviewed 584 nasopharyngeal cancer patients treated with IMRT and identified a pre-EBV cut-off value of 2010 copies/ml using ROC curves, which was very close to ours. The sensitivity and specificity for DMFS were 82.1 and 49.2% (16) . However, when applying the cut-off values of 2010 copies/ml in our patient population, the sensitivity and specificity for DMFS were 75 and 56%, which were very close to the sensitivity and specificity of 75 and 58% using our cut-off value of 2300 copies/ml. Both Peng's and our study used IMRT and AJCC seventh staging. However, there was a difference in the pattern of chemotherapy. In Peng's study, 39.9% and 77.5% of the patients received induction and concurrent chemotherapy, respectively. None of our patients received induction chemotherapy, 86% of our patients received ≥5 cycles of concurrent chemotherapy and 75% of our patients completed three cycles of adjuvant chemotherapy. Another possible explanation for the discrepancy in the pre-EBV cut-off values was the different threshold of the quantitative pre-EBV values between the two laboratories; the detectable pre-EBV rate was 77.7% in Peng's vs. 59.1% in ours. Pre-EBV cut-off values of 2010 or 2300 copies/ml may both serve as an initial guidance for risk stratification in NPC patients.
Although the post-EBV may help in treatment modification, such as the intensification of adjuvant chemotherapy regimens (21) , the use of post-EBV may be too late for adaptive treatments during concurrent chemoradiation and for the identification of patients who might benefit from neoadjuvant chemotherapy. A previous phase III study demonstrated the survival benefit of the TPF regimen in neoadjuvant setting (22) . The benefit of the adjuvant treatment in the subgroups of patients with detectable post-EBV is under investigation in many ongoing trials (NCT00370890, NCT02135042 and NCT02363400).
Considering that the DMFS varied between 80 and 83% in the modern IMRT with chemotherapy studies (4-7), we identified our patients with stage IV who had a 3-year DMFS of 72.1% and those with a pre-EBV higher than 2300 copies/ml who had 3-year DMFS of 70.1%. This Sensitivity 82% Specificity 59% PPV 31.7% NPV 93.5% for OS P, prospective; R, retrospective; F/U, follow-up; AJCC, American Joint Committee on Cancer; RT, radiation therapy; OS, overall survival; PFS, progression free survival; RFS, relapse-free survival; DFS, disease free survival; DMFS, distant metastatic free survival; PPV, positive predictive value; NPV, negative predictive value; NC, neoadjuvant chemotherapy; CCRT, concurrent chemoradiation; AC, adjuvant chemotherapy; C-RT, conventional radiation therapy; IMRT, intensity modulated radiation therapy; N/A, not available. particular group might have benefit from induction chemotherapy followed by concurrent chemoradiation (4, 6, 23, 24) . However, when using the pre-EBV cut-off value alone of as high as 50 000 copies/ml., the PPVs for predicting distant metastasis and death were just 37.7 and 50%, respectively. Thus, the pre-EBV alone was not justified for risk stratification. The combination of the pre-EBV cut-off value of 2300 copies/ml and the stage grouping allowed us to confidently identify the high-risk patients. Patients with stage III-IVb and pre-EBV values ≥2300 had a 3-year OS, PFS and DMFS of 73.2, 52.8 and 67.1%, respectively and may benefit from more aggressive treatment, such as neoadjuvant chemotherapy, for better compliance and possibly better systemic control (4, 24) . In addition, tumor and EBV response to neoadjuvant chemotherapy may serve as prognostic indicators for individualized treatment strategies in this particular subgroup (22, 25) . Zhang et al. (8) proposed a primary risk stratification based on the different stage and pre-EBV cut-off. Briefly, patients who had stage I-II with a pre-EBV <4000 copies were low-risk, while patients who had stage II with a pre-EBV ≥4000 copies/ml. were classified as high-risk.
Our result suggested that stage II-III patients with EBV <2300 had favorable outcomes to the current standard cisplatin-based chemotherapy and IMRT and might not need higher intensity treatment such as induction chemotherapy (23, 26) . The interesting subgroup was the patients with stage II and a pre-EBV ≥2300, as well as the patients with stage IV but a pre-EBV <2300; this subgroup had a 3-year DMFS of 88.3%, which was much better than the mentioned 80% DMFS reference and may not need aggressive treatment, unless they had a detectable post-EBV. Among the eight patients who had a detectable post-EBV, all were stage III-IVb with a pre-EBV ≥2300 copies/ml. Interestingly, our exploratory analysis of the combination of the age group and the pre-EBV values revealed that the low risk subgroup was patients with age <45 year with pre-EBV values <2300 copies/ml while the high-risk subgroup was patients with age ≥45 year with pre-EBV values ≥2300 copies/ml. This subgroup had a 3-year DMFS of 68%. However, this finding should be validated in the future since there was no previous study reporting this combination.
The strengths of our study are that the modern IMRT technique was performed in a prospective randomized trial, the uniform use of concurrent cisplatin-based chemotherapy followed by adjuvant cisplatin and 5FU, which is considered the standard treatment in the NCCN guideline, and the use of a commercial kit for RTQ-PCR (available in many hospitals) targeting the BamHI-W fragment region of the EBV genome, which is the most popular target in other studies (9, 12, 19, 20, 27, 28) .
Limitations of our study are, first, the lack of international harmonization and standardization of the quantitative plasma EBV measurement between our laboratory with the established centers using common calibrators and PCR master mix (29) . Second, the follow-up time was relatively short, albeit the majority of the treatment failures occurred within 3 years after the treatment (30) . Third, there were limited numbers of early stage disease in our population. A longer follow-up and validation of our pre-EBV cut-off value of 2300 copies/ml in a larger population group are warranted.
In conclusions, pre-EBV cut-off of 2300 copies/ml is an optimal value predicting OS, PFS and DMFS. The combination of pre-EBV and stage/age could identify a subgroup of high-risk patients who may need aggressive therapy.
